These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 19417110)

  • 21. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
    Jorde UP; Ennezat PV; Lisker J; Suryadevara V; Infeld J; Cukon S; Hammer A; Sonnenblick EH; Le Jemtel TH
    Circulation; 2000 Feb; 101(8):844-6. PubMed ID: 10694521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin II type 1 receptor blocker, valsartan, prevented cardiac fibrosis in rat cardiomyopathy after autoimmune myocarditis.
    Tachikawa H; Kodama M; Hui L; Yoshida T; Hayashi M; Abe S; Kashimura T; Kato K; Hanawa H; Watanabe K; Nakazawa M; Aizawa Y
    J Cardiovasc Pharmacol; 2003 Jan; 41 Suppl 1():S105-10. PubMed ID: 12688405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component.
    Neri Serneri GG; Boddi M; Modesti PA; Coppo M; Cecioni I; Toscano T; Papa ML; Bandinelli M; Lisi GF; Chiavarelli M
    Circ Res; 2004 Jun; 94(12):1630-7. PubMed ID: 15131005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
    Anand IS; Rector TS; Kuskowski M; Thomas S; Holwerda NJ; Cohn JN
    Circ Heart Fail; 2008 May; 1(1):34-42. PubMed ID: 19808268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients.
    Nakamura T; Fujii S; Hoshino J; Saito Y; Mizuno H; Saito Y; Kurabayashi M
    Hypertens Res; 2005 Dec; 28(12):937-43. PubMed ID: 16671331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [On angiotensin II receptor distribution after myocardial infarction in dogs].
    Qu XF; Li JJ; Xi Y; Shen JX; Xiu CH; Yue L; Wang GZ; Huang YL
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Apr; 37(4):358-62. PubMed ID: 19791474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of valsartan and captopril in rabbit carotid injury. Possible involvement of bradykinin in the antiproliferative action of the renin-angiotensin blockade.
    Feng TC; Ying WY; Hua RJ; Ji YY; de Gasparo M
    J Renin Angiotensin Aldosterone Syst; 2001 Mar; 2(1):19-24. PubMed ID: 11881060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined angiotensin II AT1-receptor blockade and angiotensin I-converting enzyme inhibition on survival and cardiac remodeling in chronic heart failure in rats.
    Richer C; Fornes P; Domergue V; De Gasparo M; Giudicelli JF
    J Card Fail; 2001 Sep; 7(3):269-76. PubMed ID: 11561229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
    Pu Q; Brassard P; Javeshghani DM; Iglarz M; Webb RL; Amiri F; Schiffrin EL
    J Hypertens; 2008 Feb; 26(2):322-33. PubMed ID: 18192847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroprotective role of angiotensin II type 2 receptor after transient focal ischemia in mice brain.
    Miyamoto N; Zhang N; Tanaka R; Liu M; Hattori N; Urabe T
    Neurosci Res; 2008 Jul; 61(3):249-56. PubMed ID: 18455256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin II type 1 receptor blockade with 80 and 160 mg valsartan in healthy, normotensive subjects.
    Latif F; Tandon S; Obeleniene R; Hankins SR; Berlowitz MS; Ennezat PV; Le Jemtel TH
    J Card Fail; 2001 Sep; 7(3):265-8. PubMed ID: 11561228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The angiotensin II receptor antagonist valsartan inhibits endothelin 1-induced vasoconstriction in the skin microcirculation in humans in vivo: influence of the G-protein beta3 subunit (GNB3) C825T polymorphism.
    Mitchell A; Rushentsova U; Siffert W; Philipp T; Wenzel RR
    Clin Pharmacol Ther; 2006 Mar; 79(3):274-81. PubMed ID: 16513451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Valsartan regulates the interaction of angiotensin II type 1 receptor and endothelial nitric oxide synthase via Src/PI3K/Akt signalling.
    Su KH; Tsai JY; Kou YR; Chiang AN; Hsiao SH; Wu YL; Hou HH; Pan CC; Shyue SK; Lee TS
    Cardiovasc Res; 2009 Jun; 82(3):468-75. PubMed ID: 19307231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 5th communication: hemodynamic effects of valsartan in dog heart failure models.
    Yamamoto S; Hayashi N; Kometani M; Nakao K
    Arzneimittelforschung; 1997 May; 47(5):630-4. PubMed ID: 9205777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Signal transductional mechanism of calpain involved in the regulation of rat hypertrophy myocardium mediated by overloaded pressure].
    Yang YJ; Liu HM; Zhang X; Zhang JH
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jul; 38(4):599-602, 648. PubMed ID: 17718420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of the angiotensin II type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients.
    Yang HY; Kao PF; Chen TH; Tomlinson B; Ko WC; Chan P
    J Clin Pharmacol; 2007 Mar; 47(3):397-403. PubMed ID: 17322151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The angiotensin II type 1 receptor blocker valsartan attenuates graft vasculopathy.
    Yamamoto T; Sata M; Fukuda D; Takamoto S
    Basic Res Cardiol; 2005 Jan; 100(1):84-91. PubMed ID: 15490202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Valsartan restores sarcoplasmic reticulum function with no appreciable effect on resting cardiac function in pacing-induced heart failure.
    Okuda S; Yano M; Doi M; Oda T; Tokuhisa T; Kohno M; Kobayashi S; Yamamoto T; Ohkusa T; Matsuzaki M
    Circulation; 2004 Feb; 109(7):911-9. PubMed ID: 14757694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension.
    Signorovitch J; Zhang J; Wu EQ; Latremouille-Viau D; Yu AP; Dastani HB; Kahler KH
    Curr Med Res Opin; 2010 Apr; 26(4):849-60. PubMed ID: 20141381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.